Torl Biotherapeutics, Llc
Clinical trials sponsored by Torl Biotherapeutics, Llc, explained in plain language.
-
New hope for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis study is testing an experimental drug called TORL-1-23 for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug specifically targets cancer cells that have a protein called CLD…
Phase: PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Groundbreaking cancer drug enters first human trials
Disease control Recruiting nowThis is the first study testing the experimental drug TORL-1-23 in people. Researchers aim to find a safe and effective dose for patients with advanced solid tumors, including ovarian, endometrial, and lung cancers. The study will enroll 90 participants to monitor side effects an…
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug combo tested to control advanced ovarian cancer before surgery
Disease control Recruiting nowThis study is testing whether adding an experimental drug called TORL-1-23 to standard chemotherapy helps control advanced ovarian cancer before surgery. It will involve 60 women with newly diagnosed, advanced-stage ovarian, fallopian tube, or primary peritoneal cancer whose tumo…
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC